期刊文献+

政府在转化医学实践中的角色思考 被引量:1

Government role in the practice of translational medicine
原文传递
导出
摘要 转化医学已成为了当前医药卫生学界关注的焦点。在推动转化医学发展的进程中,政府应当以规划者、投资方、协调者、监督者、引导者等多个角色,推进转化医学研究,并承担相应任务。 Translational medicine has become the current focus in the field of medicine and health. To promote the development of translational medicine, the government should play multiple roles as planner, investor, coordinator, and supervisor, and to take its due responsibilities.
出处 《中华医学科研管理杂志》 2012年第3期149-151,共3页 Chinese Journal of Medical Science Research Management
基金 上海市卫生局局级科研项目(2010204)
关键词 转化医学 政府 角色 Translational Medicine Government role
  • 相关文献

参考文献14

  • 1Wehling M. Translational medicine: can it really facilitate the transition of research" from bench to bedside"?. Eur J Clin Pharmacol,2006,62(2) :91-95.
  • 2卫生部比较医学重点实验室阜阳转化医学研究中心成立.(2009-02-02 ) [2009-06-02 ]. http://ah, anhuinews, com/ system/2009/02/02/O02200299, shtml.
  • 3中南大学.关于成立中南大学转化医学研究中心的决定.[EB/OL]. ( 2009-01-12 ) [ 2009-06-02 ]. http://ccce. CSU. edu. cn/ Html/News/xueyuangonggao/xueyuanTongzhi/2041 10668. html.
  • 4首家儿科转化医学研究所成立.[EB/OL](2009-10-23)[2009-10-24]http:// news. 163. com/09/1024/08/5MCJUGG6000120GR. html.
  • 5Re-engineering the Clinical Research Enterprise [EB/OL]. [2009-06-02]. http://nihroadmap, nih. gov/clinicalresearch/ overview-translational, asp # top.
  • 6Science and innovation investment framework 2004-2014. HM Treasury,2004.
  • 7Zerhouni E. The NIH Roadmap. Science, 2003 (302) : 63-72.
  • 8牛物谷.美政府为促进转化医学和药物开发设药物开发中心.医药经济报,2011-02-10(20).
  • 9Ofice for strategic coordination of health research. OSCHR. Chairman's first progress report,2008.
  • 10Jaillon P. Organisation of clinical research in France: thenew missions of interregional delegations for clinical research. Bull Acad Natl Med, 2008,192(5) : 929-937.

二级参考文献11

  • 1LEHMANN C U,ALTUWAIJRI M M,LI Y C, et al. Translational research in medical informatics or from theory to practice[J].Methods Inf Med,2008,47(1) :1-3.
  • 2LITTMAN B H,MARIO L D,PLEBANI M,et al. What's next in translational medicine? [J]. Clin Sci (Lond),2007,112(4) :217 227.
  • 3MARINCOLA F M. Translational Medicine:A two-way road [J].Transl Med,2003,1(1) :1-2.
  • 4JEMAL A,SIEGEI. R,WARD E,et al. Cancer statistics,2007 [J]. CA Cancer J Clin,2007,57 (1):43-66.
  • 5KRIS M G. Foreword: challenging the 'one size-fits-all ' approach of chemotherapy and radiotherapy for patients with non-small cell lung cancer [J].Lung Caneer,2008,60(Suppl 2) :S1- 2.
  • 6AMERLING R ,WINCHESTER J F ,RONCO C. Guidelines have done more harm than good [J]. Blood Purif,2008,26(1) :73-76.
  • 7MANDELL B F. Surrogate markers are not 'one size-fits all' [J]. Cleve Clin J Med,2006, 73(5) :416.
  • 8ISSA A M. Personalized medicine and the practice of medicine in the 21st century [J]. Mcgill J Med,2007,10(1):53-57.
  • 9MEYER C R. Personalized medicine[J]. Minn Med,2008,91(5) :4.
  • 10MATHEW J P,TAYLOR B S,BADER G D,et al. From bytes to bedside:data integration and computational biology for translational cancer research [J]. PLoS Comput Biol,2007,3(2) 153-162.

共引文献69

同被引文献9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部